SB-209670

• Description :

  SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki=0.2 and 18 nM, respectively) . SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty[1].

• UNSPSC :

  12352005

• Target :

  Endothelin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/sb-209670.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C([C@@H]1[C@@H](C2=CC=C(OCO3)C3=C2)C4=C(C=C(OCCC)C=C4)[C@H]1C5=CC=C(OC)C=C5OCC(O)=O)O

• Molecular Formula :

  C29H28O9

• Molecular Weight :

  520.53

• References & Citations :

  [1]E H Ohlstein, et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91 (17) :8052-6.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [157659-79-5]